AR038368A1 - Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento - Google Patents
Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamentoInfo
- Publication number
- AR038368A1 AR038368A1 ARP030100267A ARP030100267A AR038368A1 AR 038368 A1 AR038368 A1 AR 038368A1 AR P030100267 A ARP030100267 A AR P030100267A AR P030100267 A ARP030100267 A AR P030100267A AR 038368 A1 AR038368 A1 AR 038368A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- aminoalkyl
- hydroxyalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 45
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- -1 N-pyrimidin-2-yl-amine compound Chemical class 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001733 carboxylic acid esters Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto N-pirimidin-2-il-amina sustituido de la fórmula (1): en donde: R1 es halógeno o haloalquilo ( de 1 a 4 átomos de carbono), R2 es hidrógeno, halógeno, o haloalquilo (de 1 a 4 átomos de carbono), R3 es halógeno o haloalquilo (de 1 a 4 átomos de carbono), R4 es hidrógeno, alquilo (de 1 a 8 átomos de carbono), hidroxialquilo (1 a 6 átomos de carbono), o un grupo de la fórmula: -CO-R5,-CO-(CH2)m-OR6, -CO-CO-R7, -CO-CO-OR8, -CO-N(R9R10), -CO-(CH2)n-CO-R11, -CO-(CHR15)-O-(CH2)o-CO-R11, -CO-(CH2)p-O-(CH2)q-O-(CH2)r-R16, -CO-O-(CH2)s-O-CO-R17, -CO-O-(CH2)t-N(R18R19), -CO-O-(CH2)u-NH-CO-CH(NH2)-R20, o -CO-O-(CH2)w-NH-CO-R17, en donde R5 es hidrógeno, alquilo (de 1 a 8 átomos de carbono), cicloalquilo (de 3 a 8 átomos de carbono), amino, alquilamino(de 1 a 4 átomos de carbono), dialquilamino (de 1 a 4 átomos de carbono), arilo o heterociclilo, el cual es un sistema de anillo heterocíclico de 5 o 6 miembros, que tiene de 1 a 4 heteroátomos seleccionados a partir de N, O, o S; R6 es hidrógeno, alquilo (de 1 a 4 átomos de carbono), cicloalquilo (de 3 a 8 átomos de carbono), arilo, alquilo (de 1 a 4 átomos de carbono) sustituido por heterociclilo, el cual es un sistema de anillo heterocíclico de 5 o 6 miembros que tiene de 1 a 4 heteroátomos seleccionados a partir de N, O, o S, aminoalquilo (de 1 a 6 átomos de carbono), alquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 6 átomos de carbono), dialquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 6 átomos de carbono), hidroxialquilo (de 1 a 6 átomo de carbono), hidroxialquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 6 átomos de carbono), o un residuo de aminoácido, por ejemplo -CH2-CH(NH2)-COOH; R7 y R8 independientemente uno del otro son alquilo (de 1 a 4 átomos de carbono), cicloalquilo (de 3 a 8 átomos de carbono), arilo, o heterociclilo que es un sistema de anillo heterocíclico de 5 o 6 miembros que tiene de 1 a 4 heteroátomos seleccionados a partir de N, O, o S; R9 y R10 independientemente uno del otro son hidrógeno, o alquilo (de 1 a 4 átomos de carbono), o uno de R9 y R10 es hidrógeno y el otro es cicloalquilo (de 3 a 8 átomos de carbono), alquilo (de 1 a 4 átomos de carbono), arilo, o heterociclilo; R11 es alquilo (de 1 a 4 átomos de carbono), -OR12, -NR13R14, un aminoácido, un alquiléster (de 1 a 4 átomos de carbono) del mismo o un dialquiléster (de 1 a 4 átomos de carbono) del mismo, R12 es hidrógeno o alquilo (de 1 a 4 átomos de carbono); R13 y R14 independientemente uno del otro son hidrógeno, alquilo (de 1 a 4 átomos de carbono), aminoalquilo (de 1 a 6 átomos de carbono), alquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 6 átomos de carbono), dialquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 6 átomos de carbono); R15 es hidrógeno o alquilo (de 1 a 4 átomos de carbono); R16 es hidrógeno, alquilo (de 1 a 4 átomos de carbono), carboxilo o éster carboxílico, R17 es aminoalquilo (de 1 a 4 átomos de carbono), alquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 4 átomos de carbono), o dialquilo (de 1 a 4 átomos de carbono)-aminoalquilo (de 1 a 4 átomos de carbono); R18 es hidrógeno o alquilo (de 1 a 4 átomos de carbono); R19 es hidroxialquilo (de 1 a 4 átomos de carbono); R20 es alquilo (de 1 a 4 átomos de carbono), o hidroxialquilo (de 1 a 4 átomos de carbono); m es de 0 a 4; n es de 2 a 8; o es de 0 a 4; p es de 0 a 4; q es de 1 a 8; r es de 0 a 4; s es de 1 a 4; t es de 1 a 4; u es de 1 a 6; y w es de 1 a 6; una composición farmacéutica y el uso de dichos compuestos para la preparación de un medicamento para la terapia de enfermedades mediadas por la síntesis de IgE, enfermedades autoinmunes, enfermedades gastrointestinales, y rechazo crónico de trasplantes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0202381A GB0202381D0 (en) | 2002-02-01 | 2002-02-01 | Organic compounds |
| GB0221953A GB0221953D0 (en) | 2002-09-20 | 2002-09-20 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038368A1 true AR038368A1 (es) | 2005-01-12 |
Family
ID=27665364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100267A AR038368A1 (es) | 2002-02-01 | 2003-01-30 | Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20050119255A1 (es) |
| EP (1) | EP1474146B1 (es) |
| JP (1) | JP4393198B2 (es) |
| KR (1) | KR20040081159A (es) |
| CN (2) | CN101684097A (es) |
| AR (1) | AR038368A1 (es) |
| AT (1) | ATE406165T1 (es) |
| AU (1) | AU2003206810B2 (es) |
| BR (1) | BR0307379A (es) |
| CA (1) | CA2471883C (es) |
| DE (1) | DE60323205D1 (es) |
| EC (1) | ECSP045213A (es) |
| ES (1) | ES2312749T3 (es) |
| IL (1) | IL162766A0 (es) |
| MX (1) | MXPA04007395A (es) |
| NO (1) | NO20043610L (es) |
| NZ (1) | NZ534229A (es) |
| PE (1) | PE20030983A1 (es) |
| PL (1) | PL370666A1 (es) |
| PT (1) | PT1474146E (es) |
| RU (1) | RU2004126614A (es) |
| TW (1) | TW200302728A (es) |
| WO (1) | WO2003063871A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| JP2007500179A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | キナーゼ阻害剤としての２−アミノフェニル−４−フェニルピリミジン |
| EP1679309A4 (en) * | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| US20080279829A1 (en) | 2005-09-29 | 2008-11-13 | Maximilian Woisetschlaeger | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance |
| WO2009023193A1 (en) * | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| US11608329B2 (en) | 2019-12-20 | 2023-03-21 | Ikena Oncology, Inc. | Aryl hydrocarbon receptor (AHR) agonists and uses thereof |
| KR20240159754A (ko) * | 2023-04-28 | 2024-11-06 | 한국원자력의학원 | N-메틸피페라진 에탄올 카바메이트(N-methylpiperazine ethanol carbamate) 구조를 포함하는 신규 화합물 및 이의 용도 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1185039A (en) | 1966-03-31 | 1970-03-18 | Ici Ltd | Pyrimidine Derivatives and Compositions containing them |
| GB2001069B (en) | 1977-07-12 | 1982-01-20 | Scras | Pyrimidine derivatives |
| AU5319479A (en) | 1978-12-22 | 1980-06-26 | Ici Australia Limited | Pyrimidinyl amino phenoxy carboxylate derivatives |
| US4351939A (en) | 1980-10-16 | 1982-09-28 | Mead Johnson & Company | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process |
| EP0084194B1 (de) | 1982-01-14 | 1986-04-30 | MERCK PATENT GmbH | Flüssigkristallmischungen |
| FR2536071B1 (fr) | 1982-11-12 | 1986-07-11 | Sanofi Sa | Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2547821B1 (fr) | 1983-06-24 | 1985-12-06 | Sanofi Sa | Sel de 2-piperazinopyrimidine, procede pour sa preparation et compositions pharmaceutiques en contenant |
| US4659363A (en) | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
| EP0164204A1 (en) | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
| EP0172786B1 (de) | 1984-06-25 | 1991-01-30 | Ciba-Geigy Ag | Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel |
| EP0233461B2 (en) | 1986-01-13 | 2002-05-29 | American Cyanamid Company | 4,5,6-Substituted-2-pyrimidinamines |
| DE3614060A1 (de) | 1986-04-23 | 1987-10-29 | Schering Ag | Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
| US4868183A (en) | 1986-07-21 | 1989-09-19 | Otsuka Pharmaceutical Factory, Inc. | N-pyrazinyl substituted P-aminophenols |
| DE3788494D1 (de) | 1986-10-13 | 1994-01-27 | Ciba Geigy | Harnstoffe. |
| US4826990A (en) | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| DE58905007D1 (de) | 1988-04-12 | 1993-09-02 | Ciba Geigy Ag | Harnstoffe. |
| US4973690A (en) | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
| US4966622A (en) | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
| JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| AU693114B2 (en) | 1993-10-01 | 1998-06-25 | Novartis Ag | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| CN1047776C (zh) | 1993-10-01 | 1999-12-29 | 诺瓦蒂斯有限公司 | 具有药理学活性的吡啶类衍生物及其制备方法 |
| NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| JP2896532B2 (ja) | 1994-08-13 | 1999-05-31 | ユーハン コーポレーション | 新規なピリミジン誘導体およびその製造方法 |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| ES2203937T3 (es) * | 1997-03-26 | 2004-04-16 | Taisho Pharmaceutical Co., Ltd | Derivados de 4-tetrahidropiridilpirimidina. |
| IN188411B (es) | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| WO1999035140A1 (en) * | 1998-01-12 | 1999-07-15 | Novartis Ag | PYRIDINYLPYRIMIDINE AMINES AS IMMUNOGLOBULINE E (IgE) SYNTHESIS INHIBITORS |
| BR9908539A (pt) * | 1998-01-28 | 2000-12-05 | Shionogi & Co Ltda | Compostos tricìclicos |
| ATE232521T1 (de) | 1998-03-27 | 2003-02-15 | Janssen Pharmaceutica Nv | Hiv hemmende pyrimidin derivate |
| AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
| SK286264B6 (sk) * | 1998-11-17 | 2008-06-06 | Kumiai Chemical Industry Co., Ltd. | Derivát pyrimidinylbenzimidazolu alebo triazinylbenzimidazolu, medziprodukty na jeho prípravu a poľnohospodársky/záhradnícky fungicíd s jeho obsahom |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| AU4314000A (en) | 1999-04-28 | 2000-11-17 | Institute Of Medicinal Molecular Design. Inc. | Heterocyclic carboxylic acid derivatives |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
-
2003
- 2003-01-30 TW TW092102250A patent/TW200302728A/zh unknown
- 2003-01-30 AR ARP030100267A patent/AR038368A1/es not_active Application Discontinuation
- 2003-01-31 CN CN200910205037A patent/CN101684097A/zh active Pending
- 2003-01-31 BR BR0307379-3A patent/BR0307379A/pt not_active IP Right Cessation
- 2003-01-31 MX MXPA04007395A patent/MXPA04007395A/es active IP Right Grant
- 2003-01-31 IL IL16276603A patent/IL162766A0/xx unknown
- 2003-01-31 AT AT03704506T patent/ATE406165T1/de active
- 2003-01-31 DE DE60323205T patent/DE60323205D1/de not_active Expired - Fee Related
- 2003-01-31 ES ES03704506T patent/ES2312749T3/es not_active Expired - Lifetime
- 2003-01-31 EP EP03704506A patent/EP1474146B1/en not_active Expired - Lifetime
- 2003-01-31 US US10/501,445 patent/US20050119255A1/en not_active Abandoned
- 2003-01-31 RU RU2004126614/04A patent/RU2004126614A/ru not_active Application Discontinuation
- 2003-01-31 CA CA2471883A patent/CA2471883C/en not_active Expired - Fee Related
- 2003-01-31 PT PT03704506T patent/PT1474146E/pt unknown
- 2003-01-31 WO PCT/EP2003/000973 patent/WO2003063871A1/en not_active Ceased
- 2003-01-31 NZ NZ534229A patent/NZ534229A/en unknown
- 2003-01-31 CN CNA038027372A patent/CN1622807A/zh active Pending
- 2003-01-31 PE PE2003000116A patent/PE20030983A1/es not_active Application Discontinuation
- 2003-01-31 AU AU2003206810A patent/AU2003206810B2/en not_active Ceased
- 2003-01-31 KR KR10-2004-7011797A patent/KR20040081159A/ko not_active Withdrawn
- 2003-01-31 JP JP2003563561A patent/JP4393198B2/ja not_active Expired - Fee Related
- 2003-01-31 PL PL03370666A patent/PL370666A1/xx not_active Application Discontinuation
-
2004
- 2004-07-30 EC EC2004005213A patent/ECSP045213A/es unknown
- 2004-08-30 NO NO20043610A patent/NO20043610L/no not_active Application Discontinuation
-
2007
- 2007-05-23 US US11/805,515 patent/US7759357B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL370666A1 (en) | 2005-05-30 |
| PT1474146E (pt) | 2008-12-05 |
| US20050119255A1 (en) | 2005-06-02 |
| CN101684097A (zh) | 2010-03-31 |
| CA2471883A1 (en) | 2003-08-07 |
| KR20040081159A (ko) | 2004-09-20 |
| AU2003206810B2 (en) | 2006-06-29 |
| JP4393198B2 (ja) | 2010-01-06 |
| TW200302728A (en) | 2003-08-16 |
| RU2004126614A (ru) | 2005-05-27 |
| ECSP045213A (es) | 2004-09-28 |
| NZ534229A (en) | 2005-04-29 |
| US7759357B2 (en) | 2010-07-20 |
| IL162766A0 (en) | 2005-11-20 |
| EP1474146A1 (en) | 2004-11-10 |
| US20070281956A1 (en) | 2007-12-06 |
| ES2312749T3 (es) | 2009-03-01 |
| CA2471883C (en) | 2010-12-07 |
| WO2003063871A1 (en) | 2003-08-07 |
| NO20043610L (no) | 2004-10-05 |
| PE20030983A1 (es) | 2004-01-26 |
| JP2005516051A (ja) | 2005-06-02 |
| CN1622807A (zh) | 2005-06-01 |
| EP1474146B1 (en) | 2008-08-27 |
| MXPA04007395A (es) | 2005-06-17 |
| ATE406165T1 (de) | 2008-09-15 |
| DE60323205D1 (en) | 2008-10-09 |
| BR0307379A (pt) | 2004-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| ATE500251T1 (de) | Benzimidazole und ihre verwendung zur behandlung von diabetes | |
| AR077505A1 (es) | Compuestos de piridina y sus usos | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| UA110259C2 (uk) | Похідні піролопіримідину і пурину | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
| AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
| UY28578A1 (es) | Derivados de amida | |
| AR080187A1 (es) | Derivados pirazolicos condensados con heterociclos nitrogenados utiles en el tratamiento de enfermedades inflamatorias, inmunitarias y/o trastornos mieloploliferativos y composiciones farmaceuticas que los contienen. | |
| BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| PE58699A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| RU2007106180A (ru) | Производные индола, индазола или индолина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |